IGC Pharma (IGC) Income from Non-Controlling Interests (2010 - 2018)
IGC Pharma (IGC) posted quarterly Income from Non-Controlling Interests of $634.0 for Q1 2018, up 105.09% year-over-year from $309.13 in Q1 2017, and up 375.65% quarter-over-quarter from -$230.0 in Q4 2017.
IGC Pharma (IGC) Income from Non-Controlling Interests (2010 - 2018) Analysis & Trends
IGC Pharma (IGC) has reported Income from Non-Controlling Interests for 9 consecutive years, with $634.0 the latest figure, recorded in Q1 2018.
- In Q1 2018, Income from Non-Controlling Interests rose 105.09% year-over-year to $634.0; the TTM figure through Jun 2018 stood at $320.0 (down 98.42% YoY), while the FY2017 annual figure was $14399.0, up 156.02% from the prior year.
- Income from Non-Controlling Interests improved to $634.0 in Q1 2018 per IGC's latest filing, from -$230.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $38088.0 in Q4 2016 and bottomed at -$42000.0 in Q4 2015.
- Historically, Income from Non-Controlling Interests has averaged -$3364.4 across 5 years, with a median of -$5073.0 in 2016.
- Annual changes were most pronounced in 2014 — Income from Non-Controlling Interests sank 15820.44% — and 2015, when it jumped 450.89%.
- IGC Pharma's Income from Non-Controlling Interests stood at -$8882.0 in 2014, then slumped by 372.87% to -$42000.0 in 2015, then surged by 190.69% to $38088.0 in 2016, then slumped by 100.6% to -$230.0 in 2017, then jumped by 375.65% to $634.0 in 2018.
- Business Quant data shows IGC's Income from Non-Controlling Interests at $634.0 in Q1 2018, -$230.0 in Q4 2017, and -$84.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 634.00 |
| Dec 31, 2017 | -230.00 |
| Sep 30, 2017 | -84.00 |
| Jun 30, 2017 | -319.00 |
| Mar 31, 2017 | -12,449.00 |
| Dec 31, 2016 | 38,088.00 |
| Sep 30, 2016 | -5,073.00 |
| Jun 30, 2016 | 23,238.00 |
| Mar 31, 2016 | 28,298.00 |
| Dec 31, 2015 | -42,000.00 |
| Sep 30, 2015 | -16,979.00 |
| Jun 30, 2015 | 29,085.00 |
| Mar 31, 2015 | -40,118.00 |
| Dec 31, 2014 | -8,882.00 |
| Sep 30, 2014 | -28,454.00 |
| Jun 30, 2014 | -8,289.00 |
| Mar 31, 2014 | -13,660.00 |
| Dec 31, 2013 | -5,336.00 |
| Sep 30, 2013 | 181.00 |
| Jun 30, 2013 | -1,173.00 |